Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies

Table 2 Regulatory letters by releasing division/office, 1997–2011

Administration	Clinton 2nd administration				Bush administrations								Obama administration			All
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	Total
Prescription Drug Promotion	140	162	108	79	69	27	25	23	29	22	20	21	43	52	30	850
Office of Scientific Investigations	2	4	8	5	11	2	2	3	6	9	10	16	20	15	18	131
Compliance		1		1	2	12	19	10		2	1		40	17		105
Manufacturing and Product Quality	14	7	5	11	6	1		1	3	2	3	4	8	16	17	98
Security, Integrity and Recalls	7	8	1	1					4	1	20	3	6	6	2	59
Compliance Risk Management and Surveillance							1									1
Drugs and Labeling Compliance	1															1
Prescription Drug Compliance			1													1
Manufacturing and Product Quality/Division of Compliance Risk Management and Surveillance		1														1
Unapproved Drugs and Labeling Compliance															1	1
District Offices	94	116	96	98	108	81	58	71	60	81	29	85	60	89	93	1,219
Total	258	299	219	195	196	123	105	108	102	117	83	129	177	195	161	2,467

Note: 1 letter released in 1998 by the OMPQ was coauthored by the Division of Prescription Drug Compliance and Surveillance. The names of the Divisions and Offices changed over time. The most current names are included in the table.

ISSN: 1472-6963